Is double autologous transplantation in multiple myeloma superior in the age of new agents?
CTL019 in pediatric and young adult relapsed/refractory acute lymphoblastic leukemia (ALL) patients
Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Clinical implications of persisting preleukemic clones in remission in acute myeloid leukemia (AML)